Image-Guided Intensity-Modulated Radiotherapy for Clinically Localized Prostate Cancer: Targeting Pelvic Lymph Nodes

Image-Guided Radiation Therapy of Prostate Cancer

Volumn , Issue , 2008, Pages 183-196

  Roach, Mack ^a   Xia, Ping ^a   Pouliot, Jean ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 50449103774     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9781420060799-19     Document Type: Chapter

References (43)

1. Ennis RD. Uncertainties regarding pelvic radiotherapy for prostate cancer. J Clin Oncol 2004; 22:2254-2255.
2. Heidenreich A, Varga Z, Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy:high incidence of lymph node metastasis. J Urol 2002; 167:1681-1686.
3. Weckermann D, Goppelt M, Dorn R, et al. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or 1/4 10 ng/mL and biopsy Gleason score of < or 1/4 6, and their influence on PSA progression-free survival after radical prostatectomy. BJU Int 2006; 97:1173-1178.
4. Briganti A, Chun FK, Salonia A, et al. A nomogram for staging of exclusive nonobturator lymph node metastases in men with localized prostate cancer. Eur Urol 2007; 51:112-119; discussion 119-120.
5. Briganti A, Chun FK, Salonia A, et al. Critical assessment of ideal nodal yield at pelvic lymphadenectomy to accurately diagnose prostate cancer nodal metastasis in patients undergoing radical retropubic prostatectomy. Urology 2007; 69:147-151.
6. Briganti A, Karakiewicz PI, Chun FK, et al. Percentage of positive biopsy cores can improve the ability to predict lymph node invasion in patients undergoing radical prostatectomy and extended pelvic lymph node dissection. Eur Urol 2007; 51:1573-1581.
7. Schumacher MC, Burkhard FC, Thalmann GN, et al. Is pelvic lymph node dissection necessary in patients with a serum PSA <10 ng/ml undergoing radical prostatectomy for prostate cancer? Eur Urol 2006; 50:272-279.
8. Golimbu M, Morales P, Al-Askari S, et al. Extended pelvic lymphadenectomy for prostate cancer. J Urol 1979; 121:617-620.
9. Murray SK, Breau RH, Guha AK, et al. Spread of prostate carcinoma to the perirectal lymph node basin: analysis of 112 rectal resections over a 10-year span for primary rectal adenocarcinoma. Am J Surg Pathol 2004; 28:1154-1162.
10. Pagliarulo V, Hawes D, Brands FH, et al. Detection of occult lymph node metastases in locally advanced node-negative prostate cancer. J Clin Oncol 2006; 24: 2735-2742.
11. Shariat SF, Kattan MW, Erdamar S, et al. Detection of clinically significant, occult prostate cancer metastases in lymph nodes using a splice variant-specific rt-PCR assay for human glandular kallikrein. J Clin Oncol 2003; 21:1223-1231.
12. Ferrari AC, Stone NN, Kurek R, et al. Molecular load of pathologically occult metastases in pelvic lymph nodes is an independent prognostic marker of biochemical failure after localized prostate cancer treatment. J Clin Oncol 2006; 24:3081-3088.
13. Miyake H, Kurahashi T, Hara I, et al. Significance of micrometastases in pelvic lymph nodes detected by realtime reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy after neoadjuvant hormonal therapy. BJU Int 2007; 99:315-320.
14. Miyake H, Hara I, Kurahashi T, et al. Quantitative detection of micrometastases in pelvic lymph nodes in patients with clinically localized prostate cancer by real-time reverse transcriptase-PCR. Clin Cancer Res 2007; 13:1192-1197.
15. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003; 348:2491-2499.
16. Shih HA, Harisinghani M, Zietman AL, et al. Mapping of nodal disease in locally advanced prostate cancer: rethinking the clinical target volume for pelvic nodal irradiation based on vascular rather than bony anatomy. Int J Radiat Oncol Biol Phys 2005; 63:1262-1269.
17. Harisinghani MG, Saksena MA, Hahn PF, et al. Ferumoxtran-10-enhanced MR lymphangiography: does contrast-enhanced imaging alone suffice for accurate lymph node characterization? AJR Am J Roentgenol 2006; 186:144-148.
18. Asbell SO, Krall JM, Pilepich MV, et al. Elective pelvic irradiation in stage A2, B carcinoma of the prostate:Analysis of RTOG 77-06. Int J Radiat Oncol Biol Phys 1988; 15:1307-1316.
19. Roach M III, DeSilvio M, Lawton C, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression:Radiation Therapy Oncology Group 9413. J Clin Oncol 2003; 21:1904-1911.
20. Roach M III, DeSilvio M, Valicenti R, et al. Whole pelvic, “mini-pelvic” or prostate only external beam radiotherapy field following neoadjuvant and concurrent hormonal therapy:in patients treated on RTOG 9413. Int J Radiat Oncol Bio Phys 2006; 66(3):647-653.
21. Seaward SA, Weinberg V, Lewis P, et al. Improved freedom from PSA failure with whole pelvic irradiation for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 1998; 42:1055-1062.
22. Spiotto MT, Hancock SL, King CR. Radiotherapy after prostatectomy: improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients. Int J Radiat Oncol Biol Phys 2007; 69 (1):54-61.
23. Jacob R, Hanlon AL, Horwitz EM, et al. Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement. Int J Radiat Oncol Biol Phys 2005; 61:695-701.
24. Seaward SA, Weinberg V, Lewis P, et al. Identification of a high-risk clinically localized prostate cancer subgroup receiving maximum benefit from whole-pelvic irradiation. Cancer J Sci Am 1998; 4:370-377.
25. Allaf ME, Palapattu GS, Trock BJ, et al. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol 2004; 172:1840-1844.
26. Joslyn SA, Konety BR. Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology 2006; 68:121-125.
27. Partin AW, Mangold LA, Lamm DM, et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001; 58:843-848.
28. Cagiannos I, Karakiewicz P, Eastham JA, et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol 2003; 170:1798-1803.
29. Zelefsky MJ, Fuks Z, Hunt M, et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 2002; 53:1111-1116.
30. Wang-Chesebro A, Xia P, Coleman J, et al. Intensitymodulated radiotherapy improves lymph node coverage and dose to critical structures compared with threedimensional conformal radiation therapy in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2006; 66:654-662.
31. Hsu A, Pawlicki T, Luxton G, et al. A study of imageguided intensity-modulated radiotherapy with fiducials for localized prostate cancer including pelvic lymph nodes. Int J Radiat Oncol Biol Phys 2007; 68:898-902.
32. Xia P, Hwang A, Mu G, et al. Multi-adaptive-plan (MAP) IMRT to accommodate the independent movement of the prostate and pelvic-lymph nodes: a proof of principle study driven by clinical necessity. Int J Radiat Oncol Biol Phys 2007; 69(suppl 1):S724.
33. Wong JR, Cheng CW, Grimm L, et al. Clinical implementation of the world’s first Primatom, a combination of CT scanner and linear accelerator, for precise tumor targeting and treatment. Med Phys 2001; 17:271-276.
34. Jaffray DA, Siewerdsen JH, Wong JW, et al. Flat-panel cone-beam computed tomography for image-guided radiation therapy. Int J Radiat Oncol Biol Phys 2002; 53:1337-1349.
35. Pouliot J, Bani-Hashemi A, Chen J, et al. Low-dose megavoltage cone-beam CT for radiation therapy. Int J Radiat Oncol Biol Phys 2005; 61:552-560.
36. Mackie TR, Kapatoes J, Ruchala K, et al. Image guidance for precise conformal radiotherapy. Int J Radiat Oncol Biol Phys 2003; 56:89-105.
37. Morin O, Gillis A, Chen J, et al. Megavoltage cone-beam CT: system description and clinical applications. Med Dosim 2006; 31:51-61.
38. Pouliot J. Megavoltage imaging, megavoltage cone beam CT and dose-guided radiation therapy. Front Radiat Ther Oncol 2007; 40:132-142.
39. Langen KM, Zhang Y, Andrews RD, et al. Initial experience with megavoltage (MV) CT guidance for daily prostate alignments. Int J Radiat Oncol Biol Phys 2005; 62:1517-1524.
40. Moseley DJ, White EA, Wiltshire KL, et al. Comparison of localization performance with implanted fiducial markers and cone-beam computed tomography for on-line imageguided radiotherapy of the prostate. Int J Radiat Oncol Biol Phys 2007; 67:942-953.
41. Touijer K, Rabbani F, Otero JR, et al. Standard versus limited pelvic lymph node dissection for prostate cancer in patients with a predicted probability of nodal metastasis greater than 1%. J Urol 2007; 178:120-124.
42. Roach M, Marquez C, Yuo HS, et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen (PSA) and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1994; 28:33-37.
43. Briganti A, Chun FK, Salonia A, et al. Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer. BJU Int 2006; 98:788-793.